RSCM
CHRS icon

Rock Springs Capital Management’s Coherus Oncology CHRS Stock Holding History

Rock Springs Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,162,500
Closed -$20.2M – 156
2020
Q4 		$20.2M Sell
1,162,500
-502,949
-30% -$8.95M 0.43% 79
2020
Q3 		$30.5M Sell
1,665,449
-359,826
-18% -$6.69M 0.78% 40
2020
Q2 		$36.2M Buy
2,025,275
+75,275
+4% +$1.27M 0.99% 40
2020
Q1 		$31.6M Hold
1,950,000
– – 1.31% 28
2019
Q4 		$35.1M Buy
1,950,000
+70,000
+4% +$1.29M 1.11% 29
2019
Q3 		$38.1M Hold
1,880,000
– – 1.52% 20
2019
Q2 		$41.5M Buy
1,880,000
+1,210,000
+181% +$21M 1.5% 16
2019
Q1 		$9.14M Hold
670,000
– – 0.35% 86
2018
Q4 		$6.06M Hold
670,000
– – 0.29% 87
2018
Q3 		$11.1M Sell
670,000
-20,000
-3% -$355K 0.4% 80
2018
Q2 		$9.66M Sell
690,000
-5,000
-0.7% -$71.6K 0.37% 86
2018
Q1 		$7.68M Buy
695,000
+65,500
+10% +$717K 0.33% 94
2017
Q4 		$5.54M Sell
629,500
-8,900
-1% -$95.3K 0.25% 104
2017
Q3 		$8.52M Sell
638,400
-55,500
-8% -$734K 0.39% 81
2017
Q2 		$9.96M Buy
693,900
+18,900
+3% +$364K 0.5% 63
2017
Q1 		$14.3M Buy
675,000
+190,500
+39% +$4.69M 0.82% 41
2016
Q4 		$13.6M Buy
484,500
+17,000
+4% +$476K 0.91% 34
2016
Q3 		$12.5M Buy
467,500
+67,500
+17% +$1.84M 0.78% 42
2016
Q2 		$6.76M Buy
400,000
+118,000
+42% +$2.22M 0.5% 62
2016
Q1 		$5.99M Hold
282,000
– – 0.5% 67
2015
Q4 		$6.47M Sell
282,000
-3,000
-1% -$77.2K 0.49% 69
2015
Q3 		$5.71M Sell
285,000
-249,000
-47% -$7.58M 0.46% 71
2015
Q2 		$15.4M Buy
534,000
+334,949
+168% +$8.47M 1.13% 30
2015
Q1 		$6.09M Sell
199,051
-41,000
-17% -$1.06M 0.57% 61
2014
Q4 		$3.92M Buy
+240,051
New +$3.39M 0.46% 67

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rock Springs Capital Management's CHRS Position: Q1 2021 in Review

Rock Springs Capital Management sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 1,162,500 shares — an estimated $20.2M sold.

Rock Springs Capital Management first reported a position in CHRS in Q4 2014 and held it in 25 quarters. The position peaked at $41.5M in Q2 2019. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Rock Springs Capital Management reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Rock Springs Capital Management sold 1,162,500 Coherus Oncology shares in Q1 2021, an estimated $20.2M.
  • Rock Springs Capital Management first reported a position in Coherus Oncology in Q4 2014 and held it in 25 quarters.
  • Rock Springs Capital Management's Coherus Oncology position peaked at $41.5M in Q2 2019.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.